Bifidobacterium

Bifidobacterium strains constitute a genus of Gram-positive, anaerobic, saccharolytic bacteria frequently used as probiotics and increasingly engineered for therapeutic applications, particularly in cancer therapy. Their deep evolutionary lineage within Actinobacteria and capacity for carbohydrate metabolism underlie their adaptation to various host environments, with species like Bifidobacterium bifidum, Bifidobacterium longum, and Bifidobacterium breve most commonly found in humans[1][3][5]. Bifidobacteria are recognized for their ability to modulate the host immune system, counteract gut dysbiosis, and serve as delivery vectors for anti-tumor drugs and biologics due to their unique capacity to selectively colonize hypoxic tumor microenvironments. Though not a canonical drug target such as a receptor or enzyme, they play significant roles in disease modulation, especially regarding cancer, inflammation, cardiovascular, and hepatic diseases, and are generally regarded as safe, with minor exceptions in highly immunocompromised individuals[2][4][6]. In summary, "Bifidobacterium strains" is not a molecular target but refers to a diverse genus of bacteria used as therapeutic agents or vectors, requiring further specification to obtain structured, molecule-level target information[2][3][5].

Other names

bifidobacteriabifidobacterium spp.probiotic bifidobacteriaBBM

Colonization and proliferation in hypoxic tumor microenvironments (anaerobic niche targeting); Vector for drug/gene delivery; Modulation of host immune response and inflammation; Restoration of gut microbiome balance; Regulation of anti-tumor immunity (increased efficacy of immune checkpoint inhibitors).